close

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets. Its lead product ARQ 197 is an orally administered inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in microphthalmia transcription factor associated tumors, non-small cell lung cancer, pancreatic adenocarcinoma, and hepatocellular carcinoma. The company's clinical stage products also include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. It's preclinical and discovery programs comprise ARQ 621 focused on inhibition of the Eg5 kinesin spindle protein; ARQ 761, a second-generation E2F-1 activator; and BRAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	7.01
Volume	532969
Volume Avg	335492
52 Week High	8.19
52 Week Low	3.98
PE	N/A
PE (group average)	39
EPS Year	-0.20
EPS change Q/Q	-76.92%
EPS change Q/Q Yr ago	-86.36%
EPS change Q/Q next Q est	-57.14%
EPS change Y/Y	-68.75%
REV change Q/Q	78.67%
REV change Q/Q Yr ago	112.7%
EPS next Q est	-0.07
EPS next Y est	-0.64
Divident Annual	0.00
Dividend Yield	0%